Ondine Biomedical

At Ondine Biomedical, we are developing non-antibiotic, light-activated antimicrobial therapies (“photodisinfection”) to prevent and combat infections without contributing to antimicrobial resistance. Our flagship product, Steriwave®, rapidly decolonises a broad spectrum of bacteria, viruses and fungi in the nasal reservoir, a primary source of healthcare-associated infections. CE-marked and in clinical use, Steriwave helps hospitals strengthen infection prevention while reducing reliance on antibiotics. Beyond Steriwave, our pipeline includes additional photodisinfection therapies for indications such as ventilator-associated pneumonia, chronic sinusitis, and complex wounds—expanding new approaches to infection prevention while helping preserve antibiotics and reduce the risk of untreatable infections in the future.

Approach to Healthcare

At Ondine, our north star is better patient outcomes. When patients avoid infections and recover more quickly, the benefits extend beyond the individual. Fewer infections reduce strain on healthcare systems, lower costs, and help preserve the effectiveness of antibiotics. Our approach focuses on eliminating pathogens before they can cause harm. Photodisinfection enables healthcare teams to rapidly destroy bacteria, viruses, and fungi in minutes without needing to identify the pathogen first. Because photodisinfection works through a physical photochemical process rather than antibiotics, it does not contribute to antimicrobial resistance. In this sense, we see ourselves as resistance fighters—helping preserve the effectiveness of antibiotics while giving healthcare teams fast, universal tools to reduce infection risk, protect patients, and ease pressure on clinical staff and healthcare systems.

Impact of Product/Services on Healthcare

Traditional metrics often understate the true frequency and financial burden of surgical site infections (SSIs). These infections exacerbate surgical waitlists, consume scarce bed capacity, and can cause devastating patient trauma. Ondine’s Steriwave nasal photodisinfection eliminates a broad spectrum of microbes colonizing the nose in minutes, significantly reducing infection rates and antibiotic reliance. By mitigating these understated risks, we alleviate immense operational strain and staff stress. Our mission is to integrate photodisinfection into every hospital, protecting families and restoring health system resilience against the growing threat of AMR.

Innovation

Ondine is pioneering a new category of antimicrobial, by using light-sensitive agents that trigger a photochemical reaction capable of physically destroying bacteria, viruses, and fungi in minutes without contributing to antimicrobial resistance. The technology is designed as a flexible platform that can be adapted to multiple clinical settings. While Steriwave® nasal photodisinfection is already being used in hospitals internationally and is currently undergoing a pivotal Phase 3 clinical study in the United States, Ondine is also expanding the technology into new areas of care. Recent initiatives include a pilot study exploring the use of photodisinfection in intensive care units, where infection risks are particularly high.

Future Direction

Ondine’s goal is to make photodisinfection a new standard in infection prevention. In the near term, we are focused on completing our pivotal Phase 3 clinical study in the United States to support regulatory approval of nasal photodisinfection for surgical infection prevention. Beyond this milestone, we are expanding the application of our technology into additional high-risk clinical settings, including intensive care, where infection risks are particularly high. In the future, we plan to advance additional photodisinfection therapies for conditions such as chronic sinusitis, ventilator-associated pneumonia, burns, and surgical wounds. By extending this technology across multiple areas of care, we aim to give healthcare teams new tools to reduce infections, preserve antibiotics, and improve patient outcomes.